Global Society for Pharmacoeconomics and Outcomes Research
Slide 2Chris L Pashos, PhD ISPOR President, 2008-2009
Slide 3ISPOR SRBIJA
Slide 4Belgrade, Serbia
Slide 5WELCOME DOBRODO š LI ISPOR SRBIJA 1 ST INTERNATIONAL CONFERENCE
Slide 6President Vladimir Zah, K.S. B.Sc., Health Economics Consultant, Belgrade Vice-President Tanja Novakovic, MSc Pharm., Galenika a.d., President of Pharmacoeconomic Section of Pharmaceutical Society of Serbia (FDS), Belgrade Secretary/Treasurer Dr sci. ph. spec Natasa Bogavac-Stanojevic, Assoc. Educator, Faculty of Pharmacy, University of Belgrade
Slide 7Directors Dr sci. med. Ana Sabo , Professor, Medical Faculty, University of Novi Sad Dr Predrag Djukic , Consultant, Project Coordination Unit, Ministry of Health, Belgrade Dr Dragana Atanasijevic , Consultant Project Coordination Unit, Ministry of Health, Belgrade Doc.dr sci.ph Vesela Radonjic , Director, National Information Center for Medicine and Medical Devices (ALIMS), Belgrade Mr ph Danka Stefanovic , ALIMS, Belgrade Mr ph Danka Tesic , ALIMS, Belgrade Mr ph spec. Dragana Sovtic , Independent consultant for pharmaceutical issues, The Pharmaceutical Chamber of Serbia
Slide 8ISPOR A universal, instructive and logical association that encourages perfection in pharmacoeconomics and results explore and the fitting utilization of coming about data in medicinal services choices at all levels to advance the general wellbeing and prosperity
Slide 9OUR MISSION To advance the art of pharmacoeconomics and results research To encourage the interpretation of this examination into valuable data for human services leaders To guarantee that society apportions rare assets shrewdly, decently, and proficiently RESEARCH EVIDENCE DECISIONS HEALTH
Slide 10Who we are Where we are going How we will arrive
Slide 11OUR SCOPE MULTI-DISCIPLINARY Decision Analysis, Economics, Epidemiology, Modeling, Patient Reported Outcomes Assessment, Real World Data Analysis, Risk Assessment INCLUSIVE Decision Makers, Health Care Providers, Researchers, Students GEOGRAPHICALLY DIVERSE
Slide 12Over 4200 individuals From 96 nations Who We Are
Slide 13STUDENT NETWORK Who We Are 40 Student Chapters Worldwide 484 Student Members
Slide 14Who We Are ISPOR Membership Including Chapters
Slide 15ISPOR Membership including Chapters Who We Are 2400 ISPOR CHAPTER MEMBERS 4200 ISPOR MEMBERS OVER 6600 WORLDWIDE
Slide 16Who We Are Asia-Pacific China MDA-PE Hong Kong India Japan Shanghai Taiwan Thailand Australia Under improvement Malaysia South Korea Pakistan Singapore
Slide 17Who We Are Latin America Argentina Brazil Chile Colombia Mexico Venezuela Under improvement Cuba Ecuador Peru
Slide 18Who We Are Europe – Middle East Belarus Croatia Czech Republic Greece Hungary Poland Russia Serbia Slovakia Turkey Ukraine Israel Jordan
Slide 19MEMBERSHIP by Geographic Region Who We Are
Slide 20MEMBERSHIP by Work Environment Who We Are
Slide 21Who We Are MEMBERSHIP - WORK ENVIRONMENT Academia Research Groups Health Care Providers Medical Technology Firms Governments
Slide 22MEMBERSHIP by Research Interests Who We Are
Slide 23Who We Are MEMBERSHIP – RESEARCH INTERESTS Methods PROs Costs Clinical Outcomes Policy
Slide 24Who We Are ISPOR – MOVING AHEAD TOGETHER
Slide 25Where We Are Going Patients (Recipients of Health Care) Patients Health Care Providers FOSTER RESEARCH EXCELLENCE PROMOTE EDUCATION Health Care Payers Health Care Health Care Researchers PROMOTE COLLABORATION WITH DECISION MAKERS STIMULATE INTERNATIONAL GROWTH Regulators & Tech Assessors
Slide 26What We Do GLOBAL OUTREACH
Slide 27Athens, Greece - November 2008
Slide 28MEETINGS IN EUROPE What We Do
Slide 29What We Do MEETING REGISTRATION: EUROPE
Slide 30II. Medzinárodná konferencia ISPOR Slovak Chapter Zastúpenie Medzinárodnej spoločnosti pre farmakoekonomiku a klinické výstupy (ISPOR) v Slovenskej republike
Slide 31MEETINGS IN ASIA AND LATIN AMERICA What We Do
Slide 32Supporting Research & Practice Globally What We Do
Slide 33MEETINGS IN NORTH AMERICA What We Do
Slide 34MEETING REGISTRATION: NORTH AMERICA What We Do
Slide 35What We Do COLLABORATION TO MOVE THE FIELD FORWARD
Slide 36What We Do Special Interest Groups Initiated by ISPOR individuals, shaped with a particular research-centered objective. Teams Formed by the Board of Directors for a particular reason, for example, to grow Good Research Practices. Chambers Advisory bodies to ISPOR & its Board of Directors.
Slide 37What We Do PUBLICATIONS
Slide 38What We Do PUBLICATIONS
Slide 39What We Do PUBLICATIONS F u t u r e B o k s
Slide 40TOOLS What We Do
Slide 41Tools For Decision-Makers What We Do Global Health Care System Road Map Pharmacoeconomic Guidelines Around the World Managed Care Outcomes Research Digest ISPOR Comments on Health Policy
Slide 42Global Health Care Systems Road Map Overview of Country Specific Health Systems and Reimbursement Process What We Do
Slide 43Managed Care Outcomes Research Digest Searchable by administration gave, results evaluated or catchphrase What We Do
Slide 44Tools For Health Care Researchers What We Do ISPOR Research Digest of International Databases Good Research Practices
Slide 45ISPOR Research Digest What We Do Electronic database ~9000 examine thinks about from ISPOR gatherings
Slide 46Digest of International Databases Directory of Databases searchable by key properties What We Do
Slide 47Good Research Practices What We Do Published articles and reports on multidisciplinary themes
Slide 48Good Research Practices What We Do Code of Ethics Design and Research Practices Sponsorship Publication and Dissemination Relationship with Others Role of ISPOR
Slide 49Economic/Pharmacoeconomic Methods Modeling Budget Impact Analysis CEA with Clinical Trials Drug Cost Standards Economic Data Transferability Good Research Practices What We Do
Slide 50Good Research Practices What We Do Patient Reported Outcomes (PRO) Methods PRO Methods and Concepts Quality of Life Methods Preference-based Methods Population-based Methods Application of Conjoint Analysis in Outcomes Research
Slide 51Good Research Practices What We Do Real World Methods & Studies Data-based Methods Disease and Health Management Data & Methods Patient Registry Methods Medication Compliance and Persistence Methods & Studies Risk-Benefit Methods
Slide 52Good Research Practices What We Do Real World Methods & Studies (con " t) Design and Operations of Patient Registries Evaluating Health/Disease Management Programs Patient Registry Classification Strategy & Design Reliability & Validity of Data Sources for Disease & Health Management
Slide 53Good Research Practices What We Do Medical Devices & Diagnostics Outcomes Research Technology improvement issues Regulatory prerequisites Clinical results explore Economic results look into Patient-reported result inquire about Developing confirmation & repayment issues
Slide 54HEALTH TECHNOLOGY ASSESSMENT ACTIVITIES What We Do HTA & EVIDENCE-BASED DECISIONS SPECIAL INTEREST GROUP WORKING GROUPS HTA FOR REIMBURSEMENT DECISIONS HTA OF EMERGING NEW TECHNOLOGIES GLOBAL HTA USED IN HC REIMBURSEMENT
Slide 55HTA ACTIVITIES What We Do Information Roadmap of worldwide medicinal services conveyance & repayment frameworks Directory of HTA associations overall Methods Survey of strategies utilized universally as a part of HTA and arrangement making Translation Survey of procedures for embracing rising advances
Slide 56HTA ACTIVITIES What We Do ISPOR HTA Council KEY ISSUES Need for information HTA scope & innovation life cycle Methods HTA prioritization Translating data for or by approach creators
Slide 57Where We Are Going Patients (Recipients of Health Care) Patients Health Care Providers FOSTER RESEARCH EXCELLENCE PROMOTE EDUCATION Health Care Payers Health Care Health Care Researchers PROMOTE COLLABORATION WITH DECISION MAKERS STIMULATE INTERNATIONAL GROWTH Regulators & Tech Assessors
Slide 58International Society for Pharmacoeconomics and Outcomes Research
Slide 593 C ollaboration C ollegiality C ommunication (SR) 2 S cientific R igor S ocietal R elevance
Slide 60THANK YOU! HVALA!
Slide 61WELCOME DOBRODO š LI ISPOR SRBIJA 1 ST INTERNATIONAL CONFERENCE
SPONSORS
SPONSORS
SPONSORS
Subjective Case Study Research, OEIS Technologies, Learning, and Performance 
Wayne State University Undergraduate Research Conference 
Incorporating Address, Research facility, and Writing utilizing Contextual investigations
Distributed computing: More Than a Virtual Stack Diminish Espresso Executive, Stage Research salesforce Torrance, Califo
Initial 3 Steps to lead research 
G. Matthew Bonham The Maxwell School of Syracuse College Daniel Heradstveit Norwegian Organization of Universal Undertak
Practices and Preferences of Digital Natives: Informing a Research Agenda 
The New "Bill of Rights" of Data Society